Indian Pharma sector has made rapid strides in both global and domestic market. But the growth pangs were severe for domestic players eyeing greater share of global pie. The slow down in generic approvals by USFDA, the payment problems witnessed in a few developing markets since the quarter ended December and accelerated genericisation and intense compe The slow down in generic approvals by USFDA, the payment problems witnessed in a few developing markets since the quarter ended December and accelerated genericisation and intense competition together meant slower growth in global revenues for the domestic players.

But despite challenging environment, the domestic players continued their consolidation mode and are getting ready for increased CRAMS business from the global majors.

Attracted by enticing business model of the domestic pharma companies, some global players have acquired Indian pharma companies including Ranbaxy Laboratories, Matrix Laboratories etc.

Simultaneously, we also witnessed global majors like Pfizer entering deal with domestic players like Aurobindo Pharma and Claris Lifesciences unlisted for marketing their generics in the advanced markets.

So, the pharma sector is in thick of action. With availability of skilled labour at low cost, India has become favorable destination for most of Multinational companies to manufacture their products and to develop new molecules. With many blockbuster drugs about to expire in the next years and at the same time fall in the research pipeline has become major concern for the all MNC players.

To maintain bottom-line, the top MNC companies are looking towards buying the generic players or partnership with generic player to market generic drugs in advanced markets. With huge cash in hand and attractive valuation, MNCs are also acquiring the majority stake in its emerging market subsidiaries in regular, India in particular. The MNC companies Novartis, Pfizer and Merck came with buy back proposal to acquire stake in their Indian Subsidiary.

dicajytuh.web.fc2.com | Web server is down

Claris Lifesciences net profit up pc at Rs Ajanta Pharma's board meeting on May 03, Biocon to consider recommendation of final dividend.. Alembic Pharma receives USFDA tentative approval for Vi.. Glenmark Pharma receives tentative ANDA approval for Da.. Minister of State for Finance GoI. Partner- Real Estate KPMG.

Buy Sanofi India; target of Rs Reddy's Laboratories; target of Rs Hold Cadila Healthcare; target of Rs Buy Natco Pharma; target of Rs See how stocks within the sector have performed over the various time periods during the last 1 year.

You can see the price as well as the percentage change for the relevant period over the current price. DON'T KNOW WHICH SECTOR YOUR STOCK BELONGS TO?

Pharmaceuticals Stock Price, Share Price, Live BSE/NSE, Bids Offers. Sector Name Buy/Sell, news & tips, & F&O Quotes

Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol. Quotes NAVs Commodities Futures News Forum Notices Videos All.

Keep me signed in Forgot password? My Profile My Portfolio My Watchlist My Messages My Alerts.

New to Moneycontrol - Sign up now Its easy and FREE! Username should be atleast 4 characters. Username not available Suggested Usernames. Alert Your Password should contain 8 or more characters At least 1 number At least 1 symbol At least 1 upper case letter. Keep me signed in. Login Register My Portfolio My Watchlist My Messages Sign out.

Home Companies Economy Politics Interviews Cricket World Announcements.

Business Markets Stocks Economy Mutual Funds Personal Finance IPO Politics India World Technology Startups. Home Learn Evaluate Buy Track Tools Interact ETFs Investment Watch PowerYourTrade Apps.

Home Rates Experts Tools FAQs Real Assets.

Biotech Stocks To Watch And Pharma Industry News | Stock News & Stock Market Analysis - IBD

Home Planning Investing Insurance Tax Retirement Loans Credit Cards Real Estate Fixed Income Master Your Money. Quotes NAVs Commodities Futures News Messages Notices Videos All.

SBI Magnum Balanced buys 23 lakh shares of Max Financial. Spend on education sector seen falling short. Overseas transfer tax —Monster realy put to sleep for FPIs? Do you know these changes in income tax return filing process? Affordable housing emerges as a major beneficiary of Budget Time to align with the changes in income tax rules.

Impact of Budget on various sectors. Growth at 5-year low? RBI may peg 6. A disappointment for Indian renewable sector, says Mercom. Govt begins process to divest entire stake in Ferro Nigam Scrap. Is NPS a good retirement plan despite withdrawals being taxed? Budget reinvigorated FII interest; like BFSI, FMCGs: Capital gain tax becomes friendlier for honest tax payers.

Expert Advice View All.

Management Interview February 14 , Strides January 25 , Wockhardt January 25 , MD January 19 , Earnings February 28 , TECHNICAL CHARTS Compare Stocks on their Fundamentals - Revenues, Profits, EPS, ROI etc Go.

Portfolio Markets Watchlist Live TV Show Currencies Commodities Fixed Income Personal Finance Mutual Fund Stock Market India IPO Global Market Budget BSE Sensex Forum News. About us Contact Us Feedback Disclaimer Privacy Statement Terms of Use Careers Financial Terms Glossary FAQs Sitemap RSS Feed.

Disclaimer Terms of Use Privacy Statement FAQs Sitemap Feedback.